Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
15.31
-0.49 (-3.10%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
June 03, 2024
Via
Benzinga
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
May 30, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
May 10, 2024
Via
Benzinga
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
March 27, 2024
Via
Benzinga
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
May 15, 2024
These two healthcare stocks may be deeply undervalued.
Via
The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
May 08, 2024
The company doubled Wall Street's earnings views, but sales came in short.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
March 07, 2024
Via
Benzinga
Earnings Preview For Catalyst Pharmaceuticals
February 27, 2024
Via
Benzinga
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
May 01, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 22, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
March 10, 2024
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs.
Via
InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
March 05, 2024
All three have exciting programs on the way.
Via
The Motley Fool
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump In Q1
February 29, 2024
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
February 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
February 21, 2024
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety...
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.